Searched for
PHARMA COMPANY MARGINS
For investors with 1- to 2-year perspective: Strong balance sheet and growth path; 5 large-caps with upside potential up to 33%With Israel refusing to play ball in the so-called US-Iran ceasefire, it was expected that things might remain fragile with regards to the ...- Sensex jumps 238 points, Nifty closes near 24,000. 5 key factors behind today's D-Street reboundIndian equities recovered on Thursday, paring some losses from Wednesday's significant decline. The Sensex and Nifty indices showed broad-b...
- Pharma companies' Q1 margins likely to decline despite revenue growth: Goldman SachsIndian pharmaceutical firms anticipate revenue increases in the first quarter of fiscal year twenty twenty six twenty seven. Profitability ...
- Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concernsDr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue ...
- Airtel to Trent: 44 cos likely to report double-digit profit slump in Q1. Are your stocks on the list?Motilal Oswal expects 44 companies, including Bharti Airtel, Trent, IndiGo, HAL, GAIL and Cipla, to report double-digit year-on-year profit...
- Stocks in news: Adani Enterprises, Cochin Shipyard, IDFC First Bank, Premier Energies, Glenmark PharmaMarkets traded subdued on the weekly expiry day, with indices ending marginally lower. Cochin Shipyard's offer for sale saw strong investor...
- Cost pressure to keep Q1 profit growth muted for Nifty 50 companiesNifty 50 companies anticipate double-digit revenue growth for the June 2026 quarter. Profit growth is projected to remain in single digits ...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities ended lower after four straight gains as profit booking, weak global cues and caution ahead of the US Fed minutes weighed o...
- This smallcap aerospace stock could soar up to 91%, predicts NuvamaNuvama has initiated coverage on Aequs with a 'Buy' rating and a target price of Rs 444, implying a 91% upside. The brokerage expects stron...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 25%As the market makes an attempt to move upward, there is a clear preference for sectors that are focused on the domestic market. Given this,...
- Midcap stocks ignore Middle East war, AI worries to jump up to 85% in 2026. More rally or sharp correction ahead?Despite a weak first half for benchmark indices, India's midcap stocks outperformed, driven by resilient domestic inflows, stronger earning...
- Stocks in news: HDFC Bank, Vedanta Power, YES Bank, Sun Pharma, Waaree EnergiesIndian markets surged for a third straight day, buoyed by global sentiment and strong performance from heavyweight stocks like HDFC Bank an...
- For low risk-takers: 5 large-caps from different sectors with an upside potential of up to 31%Now, there is nothing wrong with being bullish, because it has always paid to be bullish. Yes, one might argue that it has not paid in the ...
- Crude oil correction could be India's next big market trigger: Rohit SeksariaIndian equities are poised for a positive shift as falling crude oil prices ease inflation and currency concerns, according to Sundaram Mut...
- Ahead of Market: 10 things that will decide stock market action on TuesdayIndian equities ended lower, snapping a two-day rally as escalating Iran-US tensions and profit booking weighed on sentiment. Sensex fell 3...
- Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...
- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
Load More
